Association of immune checkpoint inhibitors therapy with arterial thromboembolic events in cancer patients: A retrospective cohort study.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs) have emerged as a standard treatment for various malignancies. However, research indicates blocking the immune checkpoint pathway may exacerbate atherosclerotic lesions.

Objectives

We aimed to investigate whether ICI therapy increases the risk of arterial thromboembolic events (ATEs).

Methods

A retrospective cohort study was conducted on patients with histologically confirmed cancer at our institution between 2018 and 2021, using the propensity score matching method. The primary endpoint was ATEs occurrence, comprising acute coronary syndrome, stroke/transient ischemic attack, and peripheral arterial thromboembolism. Subgroup analyses assessed whether the ICI treatment effect on ATEs varied over time by limiting the maxim

SUBMITTER: Zhu J 

PROVIDER: S-EPMC10557854 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature